New drug cocktail shows promise for Hard-to-Treat lymphoma
NCT ID NCT04447716
First seen Oct 31, 2025 · Last updated May 10, 2026 · Updated 29 times
Summary
This early-phase study tests the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The drugs work by blocking cancer cell survival signals and boosting the immune system to attack the cancer. Only 4 participants were enrolled, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.